Clinical Trial: Molecular Analysis of 150 Lung Adenocarcinoma

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Observational

Official Title: Molecular Analysis of 150 Lung Adenocarcinoma With Corresponding Histopathological and Clinical Data Available

Brief Summary:

LUNG-EST is a retrospective study including 152 patients who benefit from lung surgery during the years 2012 to 2013 at Hospices civils de Lyon and with a diagnosis of lung adenocarcinomas. For all patients, clinical data and histopathological data are available. The objective of this study is to characterize these lung adenocarcinomas by the LungCarta Panel using the mass spectrometry array Sequenom. This panel could identify 214 DNA mutations and/or frameshift insert/deletion among 26 oncogenes. Once included in the study, the adenocarcinomas are also included in a Tissue MicroArray (TMA) in order to perform immunohistochemical analysis. Immunohistochemical staining with innovative antibodies are correlated with clinical, histopathological and molecular data.

Our hypothesis is that this TMA could constitute a good tool to screen interesting protein's expression.


Detailed Summary:
Sponsor: Hospices Civils de Lyon

Current Primary Outcome: Genomic DNA Mutation [ Time Frame: at diagnosis (Day 0) ]

Mutations identified by the LungCarta Panel (Sequenom) at the time of diagnosis. DNA was extracted from the lung surgical specimen.


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Hospices Civils de Lyon

Dates:
Date Received: July 20, 2016
Date Started: January 2014
Date Completion: December 2017
Last Updated: July 21, 2016
Last Verified: July 2016